Silo Pharma - Rasio total nilai perusahaan marang pendapatan SILO

Silo Pharma, Inc. (SILO) develops innovative psychedelics to combat Alzheimer's disease and PTSD. The EV/Sales multiple demonstrates the business's fundamental resilience, while the -109500.00 metric confirms the current valuation level. Prospects depend on the outcomes of depression trials and the influx of investment. However, strict DEA oversight and the risks of clinical failures create significant barriers to growth.
SILO (Silo Pharma): rincian analitis lan laporan miturut indikator

This ratio determines the market value of the business, accounting for net debt per unit of generated revenue, allowing for an assessment of the asset's fundamental value regardless of the financing structure. By analyzing historical EV/Sales trends, an investor can distinguish genuine undervaluation from a decline in efficiency, which is critical for Silo Pharma, Inc. (SILO) during the development of non-hallucinogenic drugs for the treatment of PTSD and pain.